53571-U

Ascentis^® Express 90 Å F5 (2.7 μm) HPLC Columns

L × I.D. 15 cm × 2.1 mm, HPLC Column

• Synonym(e): Core-shell (SPP) Fused Core PFP HPLC column
• UNSPSC-Code: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Eigenschaften

• product name: Ascentis^® Express F5, 2.7 μm HPLC Column, 2.7 μm particle size, L × I.D. 15 cm × 2.1 mm
• Materialien: stainless steel column
• Agentur: suitable for USP L43
• Produktlinie: Ascentis^®
• Leistungsmerkmale: endcapped
• Hersteller/Markenname: Ascentis^®
• Verpackung: 1 ea of
• Parameter: 60 °C temp. range; 600 bar max. pressure (9000 psi)
• Methode(n): HPLC: suitable; LC/MS: suitable; UHPLC-MS: suitable; UHPLC: suitable
• L × ID: 15 cm × 2.1 mm
• Oberflächenbereich: 135 m²/g
• Verunreinigungen: <5 ppm metals
• Matrix: Fused-Core particle platform; superficially porous particle
• Aktive Matrixgruppe: PFP (pentafluorophenyl) phase
• Partikelgröße: 2.7 μm
• Porengröße: 90 Å pore size
• Betriebs-pH-Wert: 2-8
• Anwendung(en): food and beverages
• Trenntechnik: reversed phase

Beschreibung

Allgemeine Beschreibung

The pentafluorophenylpropyl stationary phase of Ascentis Express F5 provides a stable reversed phase packing with electron-deficient phenyl rings due to the presence of electronegative fluorines.In addition to forming pi-pi and mildly steric interactions, F5 phases also retain compounds by polar interactions. Ascentis Express F5 can be used for basic, acidic, or neutral compounds with alternate selectivity from C18.

Anwendung

• Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high-performance liquid chromatography ion trap time-of-flight mass spectrometry.: This study employs the Ascentis^® Express F5, 2.7 μm HPLC Column to enhance the resolution and sensitivity in the analysis of lumacaftor and ivacaftor, critical medications for treating cystic fibrosis. The method provides significant insights into the stability and degradation pathways of these drugs, facilitating improved drug formulation and storage conditions (Ozcan et al., 2023).
• Stability-indicating LC-MS/MS and LC-DAD methods for robust determination of tasimelteon and high resolution mass spectrometric identification of a novel degradation product.: Utilizing the Ascentis^® Express F5, 2.7 μm HPLC Column, this research develops advanced analytical techniques for tasimelteon, a treatment for non-24-hour sleep-wake disorder. The methods ensure accurate quantification and stability assessment, crucial for clinical efficacy and patient safety (Ozcan et al., 2020).

Rechtliche Hinweise

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany